Skip to content
Menu

CareDx, Inc. CDNA

Full chart Compare
Set alert

Price alert · CDNA

All alert types
71.92 USD -2.52 (-3.39%)

Regular-session close

70.99 -0.93 -1.29%

Pre-market · Nov 20, 4:57 AM ET

71.59 Day range 76.90
15.56 52-week range 90.87
YTD
+281.74%
1 year
+350.06%

5D -5.81 (-7.43%)

72.507577.50FriMonTueWedThu72.43
Market cap
3.78B
Revenue (ttm)
497.40M
Profit margin
25.86%
EPS (ttm)
2.37
Shares out
52.54M
P/E ratio
30.35
Forward P/E
45.98
YTD return
+281.74%
1-year return
+350.06%
50-day average
67.77
Volume
878.35K
Avg volume
1.31M
Open
74.56
Previous close
74.44
Day's range
71.59 – 76.90
52-week range
15.56 – 90.87
Beta
2.49
Analysts
Buy
Price target
94.43 (+31.3%)
Earnings date
Feb 23, 2027

Key statistics

200-day average
37.51
Enterprise value
3.69B
Price / sales
7.60
Price / book
8.07
Revenue growth
39.30%
Free cash flow
130.45M
Total cash
250.48M
Total debt
29.00M
Return on equity
33.04%
Short % of float
13.93%

Fundamental scorecard

11 of 25 checks passed on CDNA’s reported financials

ValueGrowthProfitabilityHealthDividend

11of 25 checks passed

  • Value 0 of 5
  • Growth 3 of 5
  • Profitability 3 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CDNA Revenue — quarterly 139.36M
CDNA Net income — quarterly 19.29M
CDNA EPS — quarterly 0.37

Earnings

CDNA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 20260.33———
Oct 29, 2026Sep 30, 20260.25480.70+0.45+174.73%
Jul 30, 2026Jun 30, 20260.23210.37+0.14+59.41%
Apr 28, 2026Mar 31, 20260.110.34+0.23+209.09%
Feb 24, 2026Dec 31, 20250.01990.12+0.10+503.02%
Nov 4, 2025Sep 30, 2025-0.081920.0319+0.11+138.94%

Upgrades / downgrades

CDNA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2026Piper Sandlerinit—Overweight
Oct 30, 2026BTIGmainBuyBuy
Oct 27, 2026BTIGmainBuyBuy
Oct 19, 2026Canaccord GenuitymainBuyBuy
Sep 24, 2026BTIGmainBuyBuy
Sep 2, 2026Canaccord Genuityinit—Buy

About CareDx, Inc.

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
caredx.com

News

Your note

Sign in to keep a note on CDNA — it syncs with the Stock Master app.

Insider holders

CDNA insider holders
InsiderRelationLatest transactionDateShares held
BICKERSTAFF GEORGE W IIIDirectorSaleAug 4, 2026134,061
COHEN FREDERICK E. M.D. PH.D.DirectorStock GiftNov 2, 2026140,060
HAGSTROM WILLIAM ADirectorSaleJun 10, 202553,979
HANNA JOHN WALTER JRChief Executive OfficerSaleJul 15, 2026653,448
JAIN ABHISHEKChief Financial OfficerSaleApr 6, 2025337,418
KENNEDY KEITH SChief Operating OfficerSaleNov 11, 2026199,147

Institution ownership

CDNA institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.27%4,871,787350.38MSep 29, 2026
State Street Corporation4.99%2,623,064188.65MSep 29, 2026
Vanguard Capital Management LLC4.17%2,193,550157.76MSep 29, 2026
Arrowstreet Capital, Limited Partnership3.92%2,059,397148.11MSep 29, 2026
Blue Water Life Science Advisors, Lp3.31%1,740,000125.14MSep 29, 2026
ARK Investment Management, LLC3.06%1,609,054115.72MSep 29, 2026

Fund ownership

CDNA fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.96%1,554,868111.83MJun 29, 2026
BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd.2.61%1,373,55098.79MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.53%1,329,54195.62MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.51%1,321,24195.02MSep 29, 2026
ARK ETF Trust-ARK Genomic Revolution ETF2.11%1,109,82179.82MOct 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.12%588,49442.32MJun 29, 2026